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Cytotoxic CD4+ T cells in patients with B cell
chronic lymphocytic leukemia kill via a
perforin-mediated pathway
Background and Objectives.  B-cell chronic lymphocytic leukemia (B-CLL) is a clonal
expansion of CD5+B cells that accumulate due to their uncontrolled growth and resist-
ance to apoptosis. We have previously shown that up to 50% of blood CD4+ T cells in B-
CLL patients have a cytotoxicity-related CD28− CD57+ phenotype and high content of
both granzyme B and perforin (PF). In this study we investigate the cytotoxic potential of
these cells against autologous B-CLL cells.  
Design and Methods. Blood CD4+ or CD8+ T cells were positively isolated from B-CLL
patients and cultured under a range of conditions with autologous purified B-CLL cells
and with bispecific [anti-CD3 × anti-CD19] antibodies. Apoptosis of labeled B-CLL cells
was assessed using the change of mitochondrial membrane potential with the fluores-
cent dye DiOC6 and confirmed by annexin V binding.
Results. There was time- and dose-dependent killing of B-CLL cells by both CD8+ and
CD4+ T cells and this ranged from 6.6 - 68.0% for CD4+ cells and 6.4 - 57.8% for CD8+
cells. Almost complete inhibition by concanamycin A suggests that CD4+ T cells like CD8+
T cells induced apoptosis through a perforin-mediated pathway, but not via Fas/FasL (as
indicated by lack of blocking with brefeldin A), tumor necrosis factor α or TRAIL.
Interpretation and Conclusions. This study shows that blood CD4+PF+ T cells enriched
in B-CLL patients, are able to kill autologous B-CLL cells ex vivo, through bispecific anti-
bodies via a  perforin mediated mechanism.
Key words: B-CLL, CD4-cytotoxicity, perforin.
B-cell chronic lymphocytic leukemia (B-CLL) is a clonal expansion of CD5+ Bcells that accumulate in the peripher-
al blood due to their resistance to apopto-
sis.1,2 Despite the marked phenotypic as well
as chromosomal heterogeneity of leukemic
cells from individual patients, the cells char-
acteristically show prolonged survival and
over-express the anti-apoptotic Bcl-2 pro-
tein.3 A number of attempts have been made
to overcome the resistance of B-CLL cells to
apoptosis in vitro, including treatment with
antibodies to the B-cell receptor,4 CD5,3
CD20,5 and various drugs known to induce
death through apoptosis in vivo.6,7
That T cells can be induced to kill autolo-
gous and allogeneic B-CLL cells has been
shown using T-cell superantigens8 and fol-
lowing culture of autologous T cells with B-
CLL supernatant pulsed dendritic cells.9
Effector cytotoxic T lymphocytes (CTL) gen-
erated for 7 days in the presence of anti-
CD28 were able to kill autologous B-CLL
cells through an [anti-CD3 × anti-CD19] bis-
pecific antibody (BsAb).10 More recently it
was shown that normal effector CTL gener-
ated for 24 days can successfully kill allo-
geneic B-CLL cells, the activity being par-
tially blocked by inhibitors of granule exo-
cytosis and therefore thought to be attrib-
uted to perforin (PF).11 In addition, B-CLL
cells transfected with CD154 (CD40L) can
induce both proliferative and cytotoxic
responses by autologous T cells.12,13 Howev-
er, the ability of ex vivo T cells to utilize the
PF-mediated pathway to kill autologous
leukemic cells has not been shown.
It is well documented that CD8+ CTL are
the main cell type that mediate cytotoxici-
ty through both Fas/FasL and PF/granzyme
pathways.14,15 We have recently shown a
considerable expansion of CD4+ T cells with
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a cytotoxicity-related CD28− CD57+ phenotype and high
content of both granzyme B and PF in the blood of
patients with B-CLL, in some cases accounting for up to
50% of all circulating CD4+ T cells, as well as increased
expression of PF by CD8+ cells.16 Since B-CLL is often
accompanied by humoral autoimmunity17 or immuno-
deficiency,18 expansion of CD4+PF+ cells in blood of B-
CLL patients may reflect the immunoregulatory function
of these cells. CD4+PF+ T cells have also recently been
documented in several autoimmune disorders.19,20 Reg-
ulatory T cells (Tregs) have been identified as an aner-
gic CD4+CD25+CD45RBdim population.21
The aim of this study was to determine whether the
ex vivo expanded CD4+PF+ cells were able to kill autol-
ogous B-CLL cells via a PF-mediated pathway. We also
investigated whether CD4+PF+ cells expressed a regula-
tory phenotype. 
Design and Methods
Patients
With the approval of the local Ethical Committee we
studied 26 B-CLL patients (3 women and 23 men)
attending the outpatients clinics at UCLH Trust. Patients
in disease stages Rai 1-4 were studied (Table 1). Twen-
ty-three patients were deemed untreated since they
had received no treatment for at least 4 months prior
to investigation. Two patients were treated with chlo-
rambucil and one with steroids. The white blood cell
(WBC) counts varied from 2.4 to 90.4×109/L.
Cell preparation
Peripheral blood mononuclear cells (PBMC) were sep-
arated from heparinized blood on a Lymphoprep gradi-
ent (Gibco), washed twice and resuspended in RPMI-
1640 (Gibco) supplemented with 10% fetal calf serum
(FCS, Gibco) and streptomycin/penicillin (Gibco). The
cell concentration was adjusted to 5×106cells/mL.
Enrichment of CD4+ and CD8+ cells
Cells were enriched for CD4+ and CD8+ populations
using positive isolation kits (Dynal) according to the
manufacturer’s instructions. Beads were coated with
anti-CD4 or anti-CD8 mouse IgM monoclonal antibod-
ies (mAbs) and then attached beads were removed using
Detachabead (Dynal) according to the manufacturer’s
instructions. The purity of the isolated CD4+ or CD8+
cells was evaluated by staining with anti-CD4 or anti-
CD8 mAbs, conjugated to CyC (Pharmingen) and ana-
lyzed by flow cytometry. Only cell suspensions with a
purity of > 95% were used for cytotoxic assays.  
Enrichment of B-CLL cells
B cells were obtained by negative depletion of periph-
eral blood T cells and monocytes using anti-CD4, anti-
CD8  (Sigma), anti-CD14 and anti-CD3 (Pharmingen)
mAbs and Dynal beads according to the manufacturer’s
instructions. The enriched B cells were washed twice
and used for cytotoxicity assays. The purity of the iso-
lated B-CLL cells was checked by staining with CyC-
conjugated anti-CD19 and FITC-conjugated anti-CD5
mAbs, (Pharmingen) and analyzed by flow cytometry.
Only cell suspensions containing > 98% B-CLL cells
were used for cytotoxic assays. The proportion of
CD19+CD5− cells in the enriched B-cell population was
negligible. The viability of the isolated cells was moni-
tored using trypan blue, and only viable cell suspen-
sions (>95%) were used for the assays.
Cytotoxicity assay
Purified target B-CLL cells (107 cells/mL) were labeled
with the red fluorescent dye PKH26 (Sigma) according
to the manufacturer's instruction. The cells were
washed and adjusted to 105 cells/mL in RPMI-1640. The
CD4+ and CD8+ cell suspensions (effector cells)  used to
kill the target B cells were adjusted to 2.0×106 cells/mL
in RPMI-1640 and diluted so that addition of 100 µL of
each would give effector/target (E/T) cell ratios of 20:1,
10:1, 5:1 and 1:1 when added to 100 mL of target cells
in 96-well round-bottomed microplates (Nunc). Bispe-
cific anti-CD3 × anti -CD19 antibody (OKT3×RFB9) was
added at a final concentration of 2 µg/mL. Control wells
were without BsAb and contained the highest E/T ratio
(20:1) or without effector cells at 1.0×105 cells/mL in
200 µL of RPMI-1640 to control for spontaneous apop-
tosis. Cell mixtures were incubated for 4, 24 or 48 hours
at 37°C and the cytotoxicity detected only in the red
fluorescent dye marked target B-CLL cells (in FL-2) as
described below.
Bispecific antibodies were prepared using a chemical
cross-linker to couple mAb Fab’ fragments via their
hinge-region SH groups22 and the optimal concentra-
tion of BsAb for cytotoxicity was determined in pre-
liminary studies using allogeneic B-CLL target cells and
control CD8+ cells. Apoptosis was measured primarily by
the loss of mitochondrial membrane potential as
detected by decreased emission from the dye 3,3'
haematologica 2004; 89(4):April 2004436
N. Porakishvili et al.
Table 1. Patient’s data.
Stage Number of WBC×109/L
(Rai) patients Range Mean ± SD*
0 None − −
1 7 7.1-20.7 12.8±5.0
2 9 (1 - Chlorambucil) 19.2-90.4 46.0±28.1
3 6 (1 - Chlorambucil) 9.1-61.5 28.0±19.1
4 4 (1 - Steroids) 2.4-10 5.4±2.7
The patients were untreated unless otherwise stated. *Standard deviation.
 
dihexyloxacarbocyanine iodide (DiOC6, Sigma), a gen-
erally accepted method for the evaluation of effector
cell induced apoptosis.11 DiOC6 was added at a final
concentration of 40 nM, 15' prior to the end of the
incubation period and the green fluorescence of the
dye measured by flow cytometry by gating on the red-
linker marked target B-CLL cells. The results were
expressed as percentages of apoptotic cells (dull green
fluorescence) over the total including viable cells (bright
green fluorescence) minus spontaneous apoptosis seen
in the same gated population, unless indicated other-
wise. To confirm our apoptosis results obtained with
DiOC6, in some experiments apoptosis was measured by
cell binding of annexin V. Briefly, the labeled B-CLL cells
from 8 patients following incubation with CD4+ T cells
were washed twice with Ca2+-free binding buffer and
stained with annexin V-FITC (APO-1 kit, Sigma) for 10
minutes at room temperature. Green fluorescence
staining of PKH26-labeled cells was measured and the
results expressed as percentages of apoptotic annexin
V binding cells.
Mechanism of induction of apoptosis by
CD4+ T cells 
To determine whether the apoptosis of target cells
involved PF and/or Fas-mediated pathways, CD4+ or
CD8+ cells (0.2×106 in 200 µL of RPMI-1640) were pre-
treated for 2 hr at 37°C with either 100 nM of con-
canamycin A (CMA, Sigma), which causes the degrada-
tion of PF-containing granules23 or 10 µM of brefeldin
A (BFA, Sigma) which disrupts Fas/FasL-mediated inter-
actions.24 The cells were then washed three times and
co-cultured with target cells at the highest E/T cell ratio
(20:1) for 48h in the presence of BsAb. To study the
possible bystander killing through TNFα, anti-TNFα
mAb (Upstate, clone 2C8) was added at a final concen-
tration of 500 ng/mL (as recommended by the manu-
facturer), at the beginning of the culture together with
BsAb at a 20:1 E/T cell ratio for 48h.
Expression of perforin by T cells with a
regulatory phenotype
Peripheral blood mononuclear cells were prepared as
described above and stained with optimal concentra-
tions of  CyC-conjugated anti-CD4 and PE-conjugated
anti-CD25 mAbs or CyC-conjugated anti-CD4 and PE-
conjugated anti-CD45RB mAbs (Pharmingen) previous-
ly titrated to give optimum conditions. They were then
fixed, permeabilized and treated with FITC-anti-PF mAb
(Ancell) as described previously.16 In additional experi-
ments PBMC from 12 B-CLL patients and 8 controls
were stained with anti-CD4, anti-PF and PE-anti-IL-10
mAbs (Pharmingen). The cells were analyzed by flow
cytometry and the results expressed as the mean fluo-
rescence intensity (MFI) of CD45RB in PF+ and PF− CD4+
T cells and percentages of CD4+ PF+  CD25+ cells or CD4+
PF+ IL10+ cells.
Statistical analysis
The data were analyzed using Student’s t-test, corre-
lation coefficient and Mann-Whitney non-parametric
test where appropriate. Data shown in the figures rep-
resent means ± standard deviations.
Results
Both CD4+ and CD8+ cells induce apoptosis of
autologous B-CLL cells
Both CD4+ and CD8+ cells isolated from the blood of
B-CLL patients induced apoptosis of autologous
leukemic cells in the presence of anti-CD3 × anti-CD19
BsAb at an E/T ratio in the range of 20:1 - 5:1 (Figure
1). The results show that CD4+ T cells induce apoptosis
of autologous B-CLL cells.  CD8+ T cells, as expected,
also induce apoptosis. The level of apoptosis was dif-
ferent for each patient’s tumor cells and varied between
6.6 and 68.0% of DiOC6dull cells for CD4+ cells (17 out of
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Figure 1. Apoptosis of B-CLL leukemic cells induced by
CD4+ and CD8+ autologous effector cells. Effector CD4
and CD8 cells were cultured with autologous B-CLL cells
labeled with a red fluorescent linker (RFL) at different
effector/target (E/T) cell ratios with BsAb for 4-48 hours.
Apoptosis was measured by addition of the mitochondri-
al dye DiOC6 to effector/target cell mixtures for 15 mins
and the decrease in green fluorescence determined by
flow cytometry in B-CLL cells as described in the Mate-
rials and methods. The results represent the population
gated on RFL+ B-CLL cells only. This Figure show the max-
imum levels of apoptosis induced by CD4 cells (17
patients) and CD8 cells (19 patients) with spontaneous
levels of apoptosis of the B-CLL cells subtracted. Data
from two patients treated with chlorambucil and one
treated with steroids are shown by open circles and tri-
angles. A correlation coefficient was used to compare
the levels of cytotoxicity mediated by CD4+ and CD8+
cells from individual patients.
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22 patients) and 6.4 - 57.8% for CD8+ cells (19 out of
21 patients). Only negligible amounts of cytotoxicity
(<5%) were seen in the majority of the cases without
BsAb. There was no correlation between the level of
cytotoxicity induced by CD4+ or CD8+ T cells and stage
of the disease (data not shown). However, there was a
significant negative correlation (p=0.004) between the
white blood cell (WBC) count and cytotoxic activity of
CD4+ (but not CD8+ cells), the effector cells from the
patients with a WBC of more than 25×109 showing
decreased cytotoxic activity (Figure 2, pooled data). The
level of apoptosis induced by the CD4+ cells was direct-
ly related to the percentages of cells containing perforin
(correlation coefficient of 0.75): 19.8±11.9% of CD4+ PF+
cells and 49.9±20.7% of CD8+PF+ cells.
CD4+ mediated cytotoxicity is time-dependent 
Apoptosis of autologous B-CLL cells induced by both
CD4+ and CD8+ cells increased with time in culture (Fig-
ure 3). Data are shown for patients from whom suffi-
cient CD4+ T cells (4 patients, Figure 3A) and CD8+ T cells
(5 patients, Figure 3B) could be obtained for a complete
time course at an E/T ratio of 20:1 or 10:1. Spontaneous
apoptosis of the B-CLL cells alone is also shown. A time-
related increase in apoptosis appeared to be a charac-
teristic of CD4+ cells whereas that induced by CD8+ cells
had generally plateaued by 24 hours. We did not study
cytotoxicity beyond 48h, since B-CLL cells from the
majority of the patients had been killed by this time
point. To confirm these data we studied annexin V bind-
ing by B-CLL target cells in eight patients who had
shown increased apoptosis as measured by the DiOC6
assay. The results for three representative patients show
similar profiles for a time-related induction of CD4+-
induced apoptosis measured by annexin-V-FITC binding
to the cell surface of apoptotic B-CLL cells (Figure 3C).
Apoptosis of autologous B-CLL cells induced by
CD4+ and CD8+ cells was dependent on
effector cell number 
A representative experiment shows the effect of
increasing the E/T ratio on apoptosis of B-CLL cells
measured by DiOC6 staining after 24 and 48 hours in
culture (Figure 4). Data from three individual patients
show the level of CD4+ T-cell-induced apoptosis of B-
CLL cells decreased with a decreasing E/T ratio with
some minimal cytotoxicity detectable at an E/T ratio of
1:1; Figure 5A). Pooled data from patients tested at dif-
ferent E/T ratios show the same trends in dependence
of cytotoxicity on E/T ratios (Figure 5B). Interestingly, at
10:1 and 20:1 E/T ratios CD8+ cells were approaching
plateau levels for cytotoxicity as shown for individual
patients (n=3: Figure 5C) and pooled patient data (Fig-
ure 5D).
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Figure 2. Cytotoxicity by CD4+ but not CD8+ cells is relat-
ed to the white blood cell (WBC) count. Apoptosis data
from Figure 1 is plotted for two groups of patients arbi-
trarily defined by a WBC count higher (CD4+ n= 9; CD8+
n= 6) and lower (CD4+ n=15; CD8+ n=15) than 25×¥109/L.
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Figure 3. Time course for induction of apoptosis of B-
CLL cells by CD4+ and CD8+ cells. B-CLL target cells were
cultured with CD4+ or CD8+ cells at E/T cell ratios of
20:1 or 10:1 in the presence of BsAb for 4, 24 and 48hr
as described in Materials and methods. Apoptosis was
measured by green mitochondrial dye DiOC6 by gating
on B-CLL cells labeled with the red fluorescent linker as
described in Figure 1. CD4+ cells from 4 individual
patients (3A) and CD8+ cells from 5 individual patients
(3B) are shown (square symbols) together with the spon-
taneous apoptosis (round symbols) by individual target
cells. Figure 3C shows the level of binding of annexin V-
FITC to the target cells in similar experiments with CD4+
cells from 3 representative patients as effector cells.
                     
haematologica 2004; 89(4):April 2004
Cytotoxic CD4+ T cells in B-CLL 
439
CD4+ T cells kill autologous B-CLL cells via
a perforin-mediated pathway 
CD8+ T cells have been shown to induce apoptosis
primarily through a PF-mediated pathway.14,15 In order
to determine whether the apoptosis of B-CLL cells
induced by ex vivo CD4+ cells from B-CLL patients was
also mediated through a PF-dependent mechanism,
effector cells were treated with CMA prior to addition
of target leukemic cells. Cytotoxicity mediated by CD4+
cells from the majority of patients (8 out of 11) was
blocked by concanamycin (Figure 6A: p ≤ 0.025). In only
three patients, did concanamycin fail to completely
block the cytotoxic effect of CD4+ cells. As expected, the
cytotoxicity mediated by CD8+ cells at 48 hours was
completely blocked by this drug (Figure 6B, p ≤ 0.029).
To investigate the role of the Fas/FasL pathway in
induction of apoptosis by CD4+ cells, the cells were
precultured with brefeldin. In addition, to test whether
TNFα had a role in cytotoxicity we included anti-TNFα
antibodies in some cultures. Neither of these treatments
interfered with cytotoxicity mediated by either CD4+ or
CD8+ T cells. (Figures 6A and 6B).
CD4+PF+ cells do not belong to the terminally
differentiated Treg population, but are enriched
with CD25+ and IL10+ cells compared with
CD4+PF− cells
We found that PF+ CD4+ cells were enriched in
CD45RBbright cells as measured by the mean fluorescence
intensity (MFI) of CD45RB, whilst the PF− CD4+ cells con-
tained significantly more CD45RBdim cells (Figure 7A,
p=0.005). This suggests that the proportion of termi-
nally differentiated Treg cells within the PF+ CD4+ cell
Figure 4. Representative profiles showing an increase in
apoptosis with E/T cell ratio for both CD4+ and CD8+ effec-
tor cells. B-CLL target cells were cultured with CD4+ or CD8+
cells at E/T cell ratios of 20:1, 10:1, 5:1 and 1:1 in the
presence of BsAb for 48 hr. Apoptosis was measured as
described in Figure 1. The values shown have spontaneous
apoptosis subtracted. Only the statistical differences with
p values <0.05 are indicated.
Figure  5. Dose-dependence
of effector cells on the cyto-
toxic activity of CD4+ and
CD8+ cells. B-CLL target
cells were cultured with
CD4+ or CD8+ cells at E/T
cell ratios 20:1, 10:1, 5:1
and 1:1 in the presence of
BsAb for 48hr. Apoptosis
was measured as described
in Figure 1. Data are shown
for individual patients (n=3)
for CD4+ effector cells (5A)
and pooled data for CD4+
cells (5B): p values show
the differences with the
highest 20:1 E/T ratio. Indi-
vidual patient data (n=3) for
CD8+ effector cells (5C) and
pooled data for CD8+ cells
(5D) are also shown: the p
value shows the difference
between 1:1 and all other
E/T ratios used.
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population in B-CLL patients is low, as defined by
expression of CD45RB. However, significantly more PF+
CD4+ cells from B-CLL patients expressed CD25
(p=0.011) than did their control counterparts, whilst
the proportion of CD25+ cells in the PF−  CD4+population
was similar in both controls and B-CLL patients (Figure
7B). In addition, more CD4+ PF+ cells in patients with B-
CLL constitutively expressed IL-10 (Figure 7C), than did
the PF− population (8.4 ± 9.6 versus 1.5 ± 2.3, p=0.009).
This value was significantly higher than that of the CD4+
PF+ cells in healthy controls (2.1±0.9, p=0.015) sug-
gesting that in B-CLL patients the CD4+ PF+ population
is enriched with immunoregulatory T cells as deter-
mined by constitutive  expression of IL10.
Discussion
Although a property previously attributed to CD8+ T
cells, in this study we show that CD4+ T lymphocytes
were able to kill autologous B-CLL cells through a bis-
pecific antibody directed to CD3 and CD19.10 We have
recently found a significant expansion of CD4+ T cells
with the cytotoxicity-associated phenotype, expressing
perforin and granzymes in patients with B-CLL.16 In this
study we specifically investigated whether ex vivo CD4+
T cells induce apoptosis of autologous B-CLL cells
through the cytotoxicity-associated machinery that
they contain. In addition we studied whether these cells
belonged to the T regulatory population with CD4+
CD25+ CD45RBdim phenotype.
The major finding reported here is that ex vivo CD4+
cells, like CD8+ cells, were able to induce significant
apoptosis of autologous B-CLL cells in the presence of
anti-CD19×CD3 BsAb (Figure 1). There was some cor-
relation between the ability of both CD4+ and CD8+ cells
in individual patients to induce cytotoxicity (0.790),
although the individual values for apoptosis of B-CLL
cells varied from 6.6% to 68.0% for CD4+ cells and from
6.4% to 57.8% for CD8+ cells. In our study, CD4+ cells,
like CD8+ cells, induced apoptosis of the target cells in
a dose-dependent manner (Figures 4 and 5), a charac-
teristic feature of classical cytotoxic cells.11 Since we
pre-labeled the target B-CLL cells with a red membrane
linker we were able to specifically detect apoptosis in
this population and ignore any apoptosis of non-CLL B
cells. Previous studies by others have also shown killing
of malignant B-CLL cells through BsAb to CD3 and
CD19 together with anti-CD28 in a 4 hr cytotoxicity
assay.10 However, in their studies, blood lymphocytes
were activated for 9 days prior to addition of B-CLL tar-
get cells and the pathway utilized was believed to be
Fas/FasL. In our experiments we anticipated that since
the patient’s CD4+ T cells (and CD8+T cells) had the
CD28−  CD57+ phenotype of mature cytotoxic cells,16
they would directly kill the autologous tumour cells in
the presence of BsAb linking them to the target cells
upon activation via CD3.  
Although there was some limited cytotoxicity by the
CD4+ (and more so by the CD8+ T cells) measured at 4
hours, in the majority of cases the cytotoxicity by CD4+
cells was higher at 24 and 48 hours (Figures 3A and 3B).
After more prolonged exposure to the effector cells the
majority of B-CLL cells had reached the later stages of
apoptosis (ie. cell shrinkage, data not shown) indicating
irreversibility of the process. Induction of target B-CLL
apoptosis was confirmed by the binding of annexin V
(Figure 3C). Thus, unlike assays using pre-generated
cytotoxic T cells11 or NK cells, there was a time require-
ment to obtain optimum killing. This could account for
the lack of evidence in previous studies of ex vivo CD4+-
mediated cytotoxicity measured in classical 4h cyto-
toxicity assays.25
The reason for the delay in cytotoxicity is unclear. One
possibility is that CD4+ cells need to be activated to
induce apoptosis. However, both CD4+ and CD8+ cells
from two patients with high levels of perforin expres-
sion induced up to 41.8% of apoptosis of target Ramos
Figure 6. CD4+ and CD8+-mediated apoptosis is blocked by
CMA, but not BF or anti-TNFαa. CD4+ or CD8+ cells were pre-
treated for 2h with either 100 nM of CMA or 10 µmM of BF
and mixed with B-CLL target cells as described in Materials
and methods. The cells were co-cultured for 48h with BsAb
at an effector/target ratio of 20:1. In some cultures anti-
TNFαa mAb was added at the beginning of the culture. Apop-
tosis of the target cells above that of spontaneous was
expressed by the percentages of DiOC6dim B-CLL cells, marked
with a red fluorescent linker. CMA: concanamycin A; BF:
brefeldin.
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and DG75 B cells after only 4h in the presence of BsAb
(data not shown). It therefore seems likely the CD4+ T
cells are mature cytotoxic cells ex vivo. In further sup-
port of the concept that the CD4+ T cells are mature
cytotoxic cells ex vivo, CD4+ PF+ cells from control and
virus-infected individuals showed killing of EBV-infect-
ed target cells mediated through Staphylococcal
enterotoxin B within 4 hours, demonstrating that these
cells are capable of releasing perforin and killing imme-
diately.26
Another possibility is that the target B-CLL cells
themselves are not susceptible ex vivo to the action of
perforin and granzymes but acquire this susceptibility
during culture. In fact, a previous study by others indi-
cated that cytotoxicity mediated by T cells is enhanced
by pre-activation of the target B-CLL cells by phorbol
ester.27 Consistent with the necessity for the target B
cells to be activated, we found that some molecules
were up-regulated on B-CLL cells in culture with the
effector CD4+T cells. Expression of CD86 was increased
on B-CLL cells (in 5 patients) from 4.9±3.0% when cul-
tured alone for 48 hrs to 13.7±4.4% in the presence of
autologous CD4+ T cells and BsAb (p=0.0039). B-CLL
cells cultured with autologous CD8+ cells and BsAb also
up-regulated CD86, although to a lesser extent
(8.8±6.6%, p=0.082). Another possibility is that the
effector T cells might recognize leukemic cells dying in
culture and aid in their demise. Previous data from a
variety of sources have indicated that CD8+ T cells pri-
marily induce cytotoxicity through perforin-mediated
mechanisms14,15 and have suggested that the main
mechanism by which CD4+ T cells induce apoptosis is
through the Fas/FasLpathway.14,28 Since the frequency
of CD4+ T cells in B-CLL patients containing perforin is
significantly higher than in normal controls16 it was
important to determine whether CD4+ T-cell cytotoxi-
city was mediated through this molecule. Con-
canamycin A has been shown to disrupt the granules in
cytotoxic T cells and to inhibit PF-mediated cytotoxic-
ity.23,29 Our data show that, like CD8+ T-cell-mediated
cytotoxicity, CD4+ T-mediated killing is blocked by con-
canamycin A in the majority of cases (Figure 6).
Since for three patients studied, blocking of apopto-
sis induced by CD4+ T cells was not completely inhibit-
ed by concanamycin A, we tested whether other PF-
independent mechanisms could also be operating.
Brefeldin A, a Fas/FasL blocker24 failed to alter the cyto-
toxicity of either CD4+ or CD8+ T cells (Figure 6). This was
not surprising since cross-linking of Fas expressed by B-
CLL cells is not effective in inducing apoptosis30 (and
unpublished observations). Although unlikely to be play-
ing a role in our experimental system, it has recently
been shown that B-CLL cells become susceptible to Fas-
induced apoptosis after 4-5 days of activation via CD40
suggesting that this mechanism could be operating in
longer term cultures,31 as compared to a faster PF-
mediated killing. TNFα has been shown to be produced
by cytotoxic T cells,32 but in our experiments anti-TNFα
also failed to block cytotoxicity. This is not surprising
since TNFα has been shown to induce proliferation of
B-CLL cells and even protect against in vitro apoptosis.33
Another member of the TNFα family, TRAIL, which has
been shown to be produced by cytotoxic T cells34 failed
to induce apoptosis when added in vitro to B-CLL cells
Figure 7. Expression of CD45RB (A) and CD25 (B) by CD4+ PF+ and
CD4+ PF- cells in peripheral blood of B-CLL patients. PBMC from B-CLL
patients and age-matched controls were stained with CyC-conjugat-
ed anti-CD4 mAb and PE-conjugated anti-CD45RB or anti-CD25 mAbs,
fixed, permeabilized and stained with anti-PF mAb, conjugated to FITC
as described previously.16 The level of the expression by CD4+PF+ and
CD4+ PF– of CD45RB was determined by mean fluorescent intensity
(MFI: 7A). The percentages of CD4+ PF+ and CD4+PF– cells expressing
CD25 are shown in Figure 7B and the percentages of CD4+ IL-10+
cells present within each of the PF+ and PF– populations in Figure7C.
The data from 12 B-CLL patients and 8 healthy controls are shown.
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from 8 cases (data not shown). We cannot exclude that
granulysin is contributing to the cytotoxicity since it is
sensitive to CMA and is co-expressed with perforin.35-
37 This is currently under investigation. 
The significance of the expansion of functionally
potent cytotoxic CD4+ PF+ T cells in B-CLL is an impor-
tant issue. Studies by others have shown that CD4+ PF+
are increased in several autoimmune disorders19,20 and
in acute and chronic viral infections.26 Cytotoxic CD4+
T cells kill virus-infected cells primarily through per-
forin.26,38 Thus, the CD4+ T cells could be specific for
subclinical viral infections. In fact, recent studies have
suggested that there is a high frequency of CD4+ CMV-
specific T cells in patients with B-CLL (P. Moss, person-
al communication). Experiments are currently under-
way to test this possibility. Alternatively, they might
also have some specificity for tumour-associated anti-
gens and could potentially play a role in killing B-CLL
cells in vivo. That T cytotoxic precursors do exist in vivo
is suggested by the fact that autologous T lymphocytes
recognize B-CLL tumor-associated antigens such as
IgVH CDR3 region39 and that cytotoxic T cells have been
generated, in vitro, against tumor-associated antigens
from B-CLL.11,13 Our data suggest the potential role of
CD4 (and CD8) mediated cytotoxicity directed towards
autologous leukemic cells as a future component of
anti-tumor and anti-viral therapy.
Since CD4+ cells that are CD25+ and CD45RBdim have
recently been shown to be terminally differentiated T
regulatory cells21 we determined whether the PF+ CD4+
population contained cells with immunoregulatory phe-
notype. Our finding that the intensity of CD45RB  cells
within the CD4+ PF+ population in B-CLL patients was
higher than in their PF− counterparts would argue that
the PF+ population contains fewer Treg cells than does
the CD4+ PF− subset (Figure 7A). However, there were
significantly more CD25 expressing cells within the PF+
CD4+ from the B-CLL patients than from the controls
(Figure 7B). This could also suggest that they were reg-
ulatory41 or that they were simply responding to acti-
vation. Since IL-10 has also been shown to be an indi-
cator cytokine present in T regulatory cells,4,1 we exam-
ined PF+ cells for intracellular IL-10 (Figure 7C). The
CD4+ PF+ cells in B-CLL contained significantly more
intracellular IL-10, than did their PF− counterparts or PF+
cells in normal controls indicating that cells within the
CD4+ PF+ population could also have a regulatory role in
B-CLL. This is currently under investigation. With regard
to the differentiation status of the CD4+ PF+, the absence
of CD28 expression previously shown by us16 and more
recently by others in control and virus infected individ-
uals26 suggests that this population of cells has been
stimulated by antigen. However, the finding that they
are not CD45RBdim would argue against their being
mainly a chronically stimulated end-point differentiat-
ed population.21
In conclusion, we have provided evidence that the ex
vivo CD4+ PF+ T cells are capable of killing autologous B-
CLL tumor cells in vitro through a perforin-mediated
mechanism. In addition, more of these cells in B-CLL
contain IL-10 and express CD25 suggesting that they
might have a regulatory role in B-CLL. Further experi-
ments are in progress to determine the exact nature of
these cells in relation to their origin, differentiation
state, function and specificity in B-CLL patients.
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